COMMUNIQUÉS West-GlobeNewswire

Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme
27/12/2017
CHARLOTTESVILLE, Va., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN ) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of [...]
Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
27/12/2017
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data [...]
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
27/12/2017
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced [...]
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
27/12/2017
CARMIEL, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
ProQR Announces Extraordinary General Meeting of Shareholders
27/12/2017
LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq: PRQR ), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018, at 16: [...]
Blood donors step up, but more still needed
27/12/2017
OTTAWA, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Canadian Blood Services has seen a notable increase in donations since Dec. 18 when it issued an urgent call for eligible donors to fill 35,000 open appointments by Jan. 6. [...]
VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.
27/12/2017
TEL AVIV, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced the study initiation and first patient in its Phase 3 pivotal registration trial, OVAL, studying its lead candidate VB [...]
Medigus Announces First MUSE(TM) Procedure for the Treatment of GERD Performed in Israel at Shaare-Zedek Medical Center
27/12/2017
OMER, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, [...]
Novo Nordisk A/S: Share repurchase programme
27/12/2017
Bagsværd, Denmark, 27 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Orion Corporation: Managers' transactions - Westerlund Riikka
27/12/2017
ORION CORPORATION MANAGERS' TRANSACTIONS 27 DECEMBER 2017 at 9.45 EET Orion Corporation: Managers' transactions - Westerlund Riikka Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]
Herantis Pharma expands on timeline for Lymfactin studies
27/12/2017
Herantis Pharma expands on timeline for Lymfactin® studies Herantis Pharma Plc Company release 27 December 2017 at 9:00 am Herantis Pharma Plc's ("Herantis") announces a slight delay in completing patient recruitment in [...]
NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION
27/12/2017
REGULATED INFORMATION GHENT, Belgium, 27 December 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC and Jefferies [...]
NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial
26/12/2017
FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER [...]
NANOBIOTIX : La FDA donne son accord pour le lancement du premier essai d'Immuno Oncologie de Nanobiotix
26/12/2017
LA FDA DONNE SON ACCORD POUR LE LANCEMENT DU PREMIER ESSAI D'IMMUNO ONCOLOGIE DE NANOBIOTIX : UNE PHASE I/II AVEC NBTXR3 ACTIVE PAR RADIOTHERAPIE (SABR), CHEZ DES PATIENTS ATTEINTS DE CANCER DU POUMON NON A PETITES [...]
NANOBIOTIX : 2017 review and 2018 expected milestones
26/12/2017
Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company [...]
NANOBIOTIX : revue de l'année 2017 et perspectives 2018
26/12/2017
Nanobiotix : revue de l'année 2017 et perspectives 2018 Paris, France et Cambridge, Massachusetts, USA, 26 décembre 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), société française pionnière en nanomédecine [...]
HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany
26/12/2017
Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research Programs TUCSON, Ariz. and DARMSTADT, Germany, Dec. 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular [...]
UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
26/12/2017
LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome
26/12/2017
PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD [...]

Pages